These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22944059)

  • 1. [Risk factors of contrast-induced nephropathy in patients after coronary artery intervention].
    Zhao YY; Liu DW; Wang JS; Ouyang J; Zhang WZ; Zhang WJ; Meng JQ; Tang JM
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(22):1547-9. PubMed ID: 22944059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
    Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease.
    Toprak O; Cirit M; Esi E; Postaci N; Yesil M; Bayata S
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):227-35. PubMed ID: 16400673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy.
    Umruddin Z; Moe K; Superdock K
    J Nephrol; 2012; 25(5):776-81. PubMed ID: 22322819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and predictors of contrast-induced nephropathy after angioplasty for chronic total occlusions.
    Aguiar-Souto P; Ferrante G; Del Furia F; Barlis P; Khurana R; Di Mario C
    Int J Cardiol; 2010 Feb; 139(1):68-74. PubMed ID: 19056138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
    Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk factors of contrast-induced nephropathy after percutaneous coronary intervention in patients with coronary heart disease and the countermeasures].
    Zheng H; Tu Y; Ma LQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1273-6. PubMed ID: 21764713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk factors and scoring system in the prediction of contrast induced nephropathy in patients undergoing percutaneous coronary intervention].
    Fu NK; Yang SC; Chen YL; Xu J; Li Q; Li XM; Liu YY; Liu XG; Cong HL
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):551-4. PubMed ID: 22490160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy.
    Cirit M; Toprak O; Yesil M; Bayata S; Postaci N; Pupim L; Esi E
    Nephron Clin Pract; 2006; 104(1):c20-7. PubMed ID: 16685140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical survey on contrast-induced nephropathy after coronary angiography.
    Wang F; Li J; Huang B; Zhao Q; Yu G; Xuan C; Wei M; Wang N
    Ren Fail; 2013 Oct; 35(9):1255-9. PubMed ID: 23944863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.
    Kandula P; Shah R; Singh N; Markwell SJ; Bhensdadia N; Navaneethan SD
    Nephrology (Carlton); 2010 Mar; 15(2):165-70. PubMed ID: 20470274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association between high-sensitivity C-reactive protein and contrast-induced nephropathy after primary percutaneous coronary intervention].
    He YT; Tan N; Liu YH; Chen SQ; Liu Y; Huang SJ; Yang DH; Ye P; Ran P
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 May; 41(5):394-8. PubMed ID: 24021122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment.
    Toprak O; Cirit M; Yesil M; Byrne DW; Postaci N; Bayata S; Majchrzak KM; Esi E
    Kidney Blood Press Res; 2006; 29(1):2-9. PubMed ID: 16582571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients.
    Sany D; Refaat H; Elshahawy Y; Mohab A; Ezzat H
    Ren Fail; 2014 Mar; 36(2):191-7. PubMed ID: 24138570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The relationship between hyperuricemia and contrast-induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention].
    Liu YH; Tan N; Liu Y; Ye P; He YT; Ran P; Jiang L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Sep; 41(9):740-3. PubMed ID: 24331800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.